DURECT (NASDAQ:DRRX) Earns Sell Rating from Analysts at StockNews.com

StockNews.com initiated coverage on shares of DURECT (NASDAQ:DRRX) in a report released on Sunday. The brokerage issued a sell rating on the specialty pharmaceutical company’s stock.

Separately, HC Wainwright reaffirmed a “neutral” rating on shares of DURECT in a research report on Thursday, November 14th.

DURECT Stock Performance

NASDAQ:DRRX opened at $0.95 on Friday. The stock has a market cap of $29.49 million, a price-to-earnings ratio of -1.56 and a beta of 1.01. DURECT has a one year low of $0.51 and a one year high of $1.88. The business’s 50-day simple moving average is $1.07 and its 200 day simple moving average is $1.29.

Hedge Funds Weigh In On DURECT

Hedge funds have recently bought and sold shares of the company. Richmond Brothers Inc. boosted its holdings in DURECT by 39.5% in the second quarter. Richmond Brothers Inc. now owns 1,072,014 shares of the specialty pharmaceutical company’s stock worth $1,383,000 after purchasing an additional 303,670 shares during the period. Geode Capital Management LLC lifted its position in shares of DURECT by 4.8% in the 3rd quarter. Geode Capital Management LLC now owns 319,905 shares of the specialty pharmaceutical company’s stock worth $429,000 after buying an additional 14,658 shares during the last quarter. Finally, International Assets Investment Management LLC boosted its holdings in shares of DURECT by 41.3% in the 2nd quarter. International Assets Investment Management LLC now owns 21,550 shares of the specialty pharmaceutical company’s stock valued at $28,000 after buying an additional 6,300 shares during the period. 28.03% of the stock is currently owned by institutional investors and hedge funds.

DURECT Company Profile

DURECT Corporation, a biopharmaceutical company, develops medicines based on its epigenetic regulator program. The company's lead product larsucosterol (DUR-928), an endogenous, orally bioavailable small molecule that is in Phase IIb clinical trial to play a regulatory role in lipid metabolism, stress and inflammatory responses, and cell death and survival to treat alcohol-associated hepatitis, as well as completed Phase Ib clinical trial to treat patients with nonalcoholic steatohepatitis.